JUND Knockout Jurkat Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population in the Jurkat human T-cell leukemia line, in which the JUND gene has been disrupted. This genetically mixed population serves as a loss-of-function model for studying the JUND transcription factor, a core component of the AP-1 complex. The polyclonal format avoids the artifacts of clonal selection and maintains the inherent signaling heterogeneity of the parental line, making it well-suited for functional genomics and pathway analysis in an immune-cell context.
Jurkat cells are an immortalized human T-lymphocyte line originally derived from a patient with acute T-cell leukemia. They recapitulate key features of helper T cells and are employed extensively in studies of adaptive immunity, T-cell receptor signaling, and cytokine production. These cells retain functional MAPK cascades and AP-1 transcription factor machinery, making them an appropriate host for examining the role of JUND in leukemogenesis and T-cell activation.
JUND is a basic leucine zipper transcription factor that dimerizes with c-Fos, c-Jun, ATF2, or CREB1 to form the AP-1 complex. It operates downstream of the JNK (MAPK8) and ERK (MAPK1) signaling pathways, which are stimulated by TNF-??, IL-1??, EGF, and PDGF. In the JNK cascade, MEKK1 phosphorylates MKK4, which in turn activates JNK, leading to phosphorylation of JUND and c-Jun. Activated AP-1 then transactivates a battery of target genes, including CCND1, IL-2, MMP-9, and Bcl-2 family members, thereby regulating cell cycle progression, cytokine release, matrix remodeling, and apoptosis.
Disruption of JUND in Jurkat cells is expected to impair AP-1-dependent transcription, attenuating the expression of downstream effectors such as IL-2 and CCND1. This may lead to reduced cell proliferation, altered cytokine secretion profiles, and increased sensitivity to apoptotic signals. The polyclonal nature of the knockout pool preserves the natural genetic and signaling variability of the parental Jurkat line, offering a more physiologically relevant model than monoclonal derivatives for studying JUND function in leukemic T cells.
These JUND knockout Jurkat polyclonal cells are suitable for a wide range of assays, including western blotting for JUND, RT-qPCR for JUND mRNA, RNA-seq for transcriptomic analysis, AP-1 luciferase reporter assays, and flow cytometry for cell cycle and apoptosis. Additional readouts such as phospho-JNK immunoblotting and IL-2 ELISA enable detailed pathway interrogation. The model supports research into T-cell leukemia, MAPK signaling, and inflammation, and is ideal for drug-target validation. For further information, contact Ascent Research.
